Immunophenotyping of Acute Leukemias and Myelodysplastic Syndromes

Cytometry Part A

Volumn 58, Issue 1, 2004, Pages 62-71

  Orfao, Alberto ^a,c   Ortuño, Francisco ^b   De Santiago, Maria ^a   Lopez, Antonio ^a   San Miguel, Jesus ^a,b  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD33 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; MICROSOMAL AMINOPEPTIDASE; MONOCLONAL ANTIBODY; STEM CELL FACTOR RECEPTOR;

ACUTE LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; B LYMPHOCYTE; CANCER CLASSIFICATION; CANCER CYTODIAGNOSIS; CELL DIFFERENTIATION; CELL LINEAGE; CELL MATURATION; CELL STRUCTURE; CYTOGENETICS; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; FOLLOW UP; HUMAN; IMMUNOCHEMISTRY; IMMUNOPHENOTYPING; LEUKEMIA CELL; MINIMAL RESIDUAL DISEASE; MYELODYSPLASTIC SYNDROME; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STEM CELL;

EID: 1542514868     PISSN: 15524922     EISSN: None     Source Type: Journal    
DOI: 10.1002/cyto.a.10104     Document Type: Review

References (95)

1. Greaves MF, Rao J, Hariri G, Verbi W, Catovsky D, Kung P, Goldstein G. Phenotypic heterogeneity and cellular origins of T cell malignancies. Leuk Res 1981;5:281-299.
2. Janossy G, Greaves MF, Capellaro D, Roberts M, Goldstone AH. Membrane marker analysis of "lymphoid" and myeloid blast crisis in PH1 positive (chronic myeloid) leukemia. Haematol Blood Transfus 1977;20:97-107.
3. Janossy G, Bollum FJ, Bradstock KF, Ashley J. Cellular phenotypes of normal and leukemic hemopoietic cells determined by analysis with selected antibody combinations. Blood 1980;56:430-441.
4. Janossy G, Hoffbrand AV, Greaves MF, Ganeshaguru K, Pain C, Bradstock KF, Prentice HG, Kay HE, Lister TA. Terminal transferase enzyme assay and immunological membrane markers in the diagnosis of leukaemia: a multiparameter analysis of 300 cases. Br J Haematol 1980;44:221-234.
5. Cordell JL, Fallini B, Erber WN, Ghosh AK, Abdulaziz Z, McDonald S, Pulford KAF, Stein H, Mason DY. Immunoenzymatic labelling of monoclonal antibodies using immunocomplexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP) complexes. J Histochem Cytochem 1984;32:219-229.
6. Orfao A, Schmitz G, Brando B, Ruiz-Arguelles A, Basso G, Braylan R, Rothe G, Lacombe F, Lanza F, Papa S, Lucio P, San Miguel JF. Clinically useful information provided by the flow cytometric immunophenotyping of hematological malignancies: current status and future directions. Clin Chem 1999;45:1708-1717.
7. Ault KA. Between the idea and the reality falls the shadow: clinical flow cytometry comes of age? Cytometry 1988;3(suppl):2-6. 8.
8. Tarnok A, Gerstner AO. Clinical applications of laser scanning cytometry. Cytometry 2002;50:133-143.
9. Greaves M, Janossy G. Patterns of gene expression and the cellular origins of human leukaemias. Biochim Biophys Acta 1978;516:193-230.
10. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HT, Sultan C. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976;33:451-458.
11. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HT, Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-199.
12. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HT, Sultan C. Criteria for the diagnosis of acute leukaemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Ann Int Med 1985; 103:460-462.
13. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HT, Sultan C. Proposal for the recognition of minimally differentiated acute myeloid leukaemias (AML-MO). Br J Haematol 1991;74:325-329.
14. Bene MC, Bernier M, Castoldi G, Faure GC, Knapp W, Ludwig WD, Matutes E, Orfao A, Van't Veer M on behalf of EGII. (European Group on Immunological Classification of Leukemias). Impact of immunophenotyping on management of acute leukemias. Haematologica 1999;84:1024-1034.
15. Orfao A, Chillon MC, Bortoluci AM, Lopez-Berges MC, Garcia-Sanz R, Gonzalez M, Tabernero MD, Garcia-Marcos MA, Rasillo AI, Hernández-Rivas JM, San Miguel JF. The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML-RAR-alpha gene rearrangements. Haematologica 1999;84:405-412.
16. Ortuño Giner F, Orfao A. Aplicación de la citometria de flujo al diagnóstico y seguimiento inmunofenotipico de las leucemias agudas. Med Clin (Barc) 2002;118:423-436.
17. De Zen L, Orfao A, Cazzaniga G, Masiero L, Cocito MG, Spinelli M, Rivolta A, Biondi A, Basso G. Quantitative multiparametric immunophenotyping in acute lymphoblastic leukemia. Correlation with specific genotype. IETV6/AML1 ALLs identification. Leukemia 2000;14: 1225-1231.
18. Tabernero MD, Bortoluci AM, Alaejos I, Lopéz-Berges MC, Rasillo A, Garcia-Sanz R, Garcia M, Sayagues JM, González M, Mateo G, San Miguel JF, Orfao A. Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13 and CD38 expression. Leukemia 2001;15: 406-414.
19. Weir EG, Borowitz MJ. Flow cytometry in the diagnosis of acute leukemia. Semin Hematol 2001;38:124-138.
20. Borowitz MJ, Rubnitz J, Nash M, Pullen DJ, Camitta B. Surface antigen phenotype can predict TEL-AML1 rearrangement in childhood B-precursor ALL: a pediatric oncology group study. Leukemia 1998;12: 1764-1770.
21. Borowitz MJ, Hunger SP, Carroll AJ, Shuster JJ, Pullen DJ, Steuber CP, Cleary ML. Predictability of the t(1;19)(q23;p13) from surface antigen phenotype: implications for screening cases of childhood acute lymphoblastic leukemia for molecular analysis: a pediatric oncology group study. Blood 1993;82:1086-1091.
22. Navid F, Mosijczuk AD, Head DR, Borowitz MJ, Carroll AJ, Brandt JM, Link MP, Rozans MK, Thomas GA, Schwenn MR, Shields DJ, Vietti TJ, Pullen DJ. Acute lymphoblastic leukemia with the (8;14)(q24;q32) translocation and FAB L3 morphology associated with a B-precursor immunophenotype: the pediatric oncology group experience. Leukemia 1999;13:135-141.
23. Szczepanski T, Orfao A, van der Velden VH, San Miguel JF, van Dongen JJM. Minimal residual disease in leukaemia patients. Lancet Oncol 2001;2:409-417.
24. Campana D. Determination of minimal residual disease in leukaemia patients. Br J Haematol 2003;121:823-838.
25. Vidriales MB, Orfao A, San-Miguel JF. Immunologic monitoring in adults with acute lymphoblastic leukemia. Curr Oncol Rep 2003;5: 413-418.
26. Larson RA, Boogaerts M, Estey E, Karanes C, Stadtmauer EA, Sievers EL, Mineur P, Bennett JM, Berger MS, Eten CB, Munteanu M, Loken MR, Van Dongen JJ, Bernstein ID, Appelbaum FR, Mylotarg Study Group. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 2002;16:1627-1636.
27. Tallman MS. Monoclonal antibody therapies in leukemias. Semin Hematol 2002;39 (suppl 3):12-19.
28. Elguetany, MT. Surface marker abnormalities in myelodysplastic syndromes. Haematologica 1998;83:1104-1115.
29. Orfao A, de Santiago M, Matarraz S, Lopez A, del Cañizo MC, Fernández ME, Villaron E, Vidriales B, Suarez L, Ortuño F, Escribano L, San Miguel JF. Contribución del inmunofenotipo al estudio de los sindromes mielodisplasicos. Haematologica 2003;88(supp 6):269-275.
30. Brown G, Greaves, MF, Lister TA, Rapson N, Papamichael M. Expression of human T and B lymphocyte cell-surface markers on leukaemic cells. Lancet 1974;2:753-755.
31. Chessells JM, Hardisty RM, Rapson NT, Greaves MF. Acute lymphoblastic leukaemia in children: classification and prognosis. Lancet 1977;2:1307-1309.
32. Janossy G, Bollum FJ, Bradstock KF, McMichael A, Rapson N, Greaves MF. Terminal transferase-positive human bone marrow cells exhibit the antigenic phenotype of common acute lymphoblastic leukemia. J Immunol 1979;123:1525-1529.
33. Foa R, Baldini L, Cattoretti G, Foa P, Gobbi M, Lauria F, Madon E, Masera G, Miniero R, Paolucci P, et al. Multimarker phenotypic characterization of adult and childhood acute lymphoblastic leukaemia: an Italian multicentre study. Br J Haematol 1985;61:251-259.
34. Loken MR, Shah VO, Dattilio KL, Civin CI. Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development. Blood 1987;70:1316-1324.
35. Ciudad J, San Miguel JF, Lopez-Berges MC, Garcia-Marcos MA, González M, Vazquez L, del Cañizo MC, Lopez A, van Dongen JJM, Orfao A. Detection of abnormalities in B-cell differentiation pattern is a useful tool to predict relapse in precursor-B-ALL. Br J Haematol 1999;104: 695-705.
36. Lucio P, Parreira A, van den Beemd MWM, van Lochem EG, van Wering ER, Baars E, Porwit-MacDonald A, Bjorklund E, Gaipa G, Biondi A, Orfao A, Janossy G, van Dongen JM, San Miguel JF. Flow cytometric analysis of normal and leukemic bone marrow B-cell differentiation: a frame of reference for the detection of minimal residual disease in precursor B-ALL patients. Leukemia 1999;13:419-427.
37. Dworzak MN, Fritsch G, Froschl G, Printz D, Gadner H. Four-color flow cytometric investigation of terminal deoxynucleotidyl transferase-positive lymphoid precursors in pediatric bone marrow: CD79a expression precedes CD19 in early B-cell ontogeny. Blood 1998;92:3203-3209.
38. Menendez P, Prosper F, Bueno C, Arbona C, San Miguel JF, Garcia Conde J, Sola C, Cortes Funes H, Orfao A. Sequential analysis of CD34+ and CD34- cell subsets in peripheral blood and leukapheresis products from breast cancer patients mobilised with SCF plus G-CSF and cyclophosphamide. Leukemia 2001;15:430-439.
39. Rudin CM, Thompson CB. B-cell development and maturation. Semin Oncol 1998;25:435-446.
40. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, Van't Veer MB for the European Group for the Immunological Characterisation of Leukaemias. Proposals for the immunological classification of acute leukemias. Leukemia 1995;9:1783-1786.
41. Reinherz EL, Kung PC, Goldstein G, Levey RH, Schlossman SF. Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage. Proc Natl Acad Sci USA 1980;77:1588-1592.
42. Hurwitz CA, Loken MR, Graham ML, Karp JE, Borowitz MJ, Pullen DJ, Civin CI. Asynchronous antigen expression in B lineage acute lymphoblastic leukemia. Blood 1988;72:299-307.
43. Pui C, Frankel LS, Caroll AJ, Raimondi SC, Shuster JJ, Head DR, Crist WM, Land VJ, Pullen J, Steuber CP, Behm FG, Borowitz MJ. Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse. Blood 1991;78:1327-1337.
44. Wuchter C, Harbott J, Schoch C, Schnittger S, Borkhardt A, Karawajew L, Ratei R, Ruppert V, Haferlach T, Creutzig U, Dorken B, Ludwig WD. Detection of acute leukemia cells with mixed lineage leukemia (MLL) gene rearrangements by flow cytometry using monoclonal antibody 7.1. Leukemia 2000;14:1232-1238.
45. Coustan-Smith E, Sancho J, Hancock ML, Razzouk BI, Ribeiro RC, Rivera GK, Rubnitz JE, Sandlund JT, Pui CH, Campana D. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood 2002;100: 2399-2402.
46. Lucio P, Gaipa G, van Lochem EG, van Wering ER, Porwit MacDonald A, Faria T, Bjorklund E, Biondi A, van den Beemd MWM, Baars E, Vidriales B, Parreira A, van Dongen JJM, San Miguel JF, Orfao A. BIOMED-1 concerted action report - flow cytometric immunophenotyping of precursor-B ALL with standardized triple-stainings. Leukemia 2001;15:1185-1192.
47. Porwit-MacDonald A, Bjorklund E, Lucio P, van Lochem EG, Mazur J, Parreira A, van den Beemd MWM, van Wering ER, Baars E, Gaipa G, Biondi A, Ciudad J, van Dongen JJM, San Miguel JF, Orfao A. BIOMED-1 concerted action report: flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T-cell acute lymphoblastic leukemia (T-ALL). Leukemia 2000;14:816-825.
48. Subira D, Castañon S, Aceituno E, Hernandez J, Jimenez-Garofano, Jimenez A, Jimenez AM, Roman A, Orfao A. Flow cytometric analysis of cerebrospinal fluid samples and its utility in routine clinical practice. Am J Clin Pathol 2002; 117:952-958.
49. Pui CH, Williams DL, Roberson PK, Raimondi SC, Behm FG, Lewis SH, Rivera GK, Kalwinsky DK, Abromowitch M, Crist WM, et al. Correlation of karyotype and immunophenotype in childhood acute lymphoblastic leukemia. J Clin Oncol 1988;6:56-61.
50. DiGiuseppe JA, Borowitz MJ. Clinical applications of flow cytometric immunophenotyping in acute lymphoblastic leukemia. In: Stewart CC, Nicholson JKA, editors. Immunophenotyping. New York; John Wiley & Sons Inc.; 2000. p 161-180.
51. Karawajew L, Ruppert V, Wuchter C, Kosser A, Schrappe M, Dorken B, Ludwig WD. Inhibition of in vitro spontaneous apoptosis by IL-7 correlates with bcl-2 up-regulation, cortical/mature immunophenotype, and better early cytoreduction of childhood T-cell acute lymphoblastic leukemia. Blood 2000;96:297-306.
52. Terstappen LW, Hollander Z, Meiners H, Loken MR. Quantitative comparison of myeloid antigens on five lineages of mature peripheral blood cells. J Leukoc Biol 1990;48:138-148.
53. Almeida J, Bueno C, Alguero MC, Sanchez ML, de Santiago M, Escribano L, Diaz Agustin B, Vaquero JM, Laso FJ, San Miguel JF, Orfao A. Comparative analysis of the morphological, cytochemical, immunophenotypical, and functional characteristics of normal human peripheral blood lineage(-)/CD16(+)/HLA-DR(+)/CD14(-/1o) cells, CD14(+) monocytes, and CD16(-) dendritic cells. Clin Immunol 2001;100:325-338.
54. Terstappen LW, Loken MR. Myeloid cell differentiation in normal bone marrow and acute myeloid leukemia assessed by multi-dimensional flow cytometry. Anal Cell Pathol 1990;2:229-240.
55. Terstappen LW, Safford M, Loken MR. Flow cytometric analysis of human bone marrow. III. Neutrophil maturation. Leukemia 1990;4: 657-663.
56. Wells DA, Loken MR. Normal antigen expression in hematopoiesis. In: Stewart CC, Nicholson JKA, editors. Immunophenotyping. New York: John Wiley & Sons Inc.; 2000. p 133-160.
57. Macedo A, Orfao A, Gonzalez M, Vidriales MB, Lopez-Berges MC, Martinez A, San Miguel JF. Immunological detection of blast cell subpopulations in acute myeloblastic leukemia at diagnosis: implications for minimal residual disease studies. Leukemia 1995;9:993-998.
58. Terstappen LW, Safford M, Konemann S, Loken MR, Zurlutter K, Buchner T, Hiddemann W, Wormann B. Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis. Leukemia 1992;6:70-80.
59. Drexler HG. Myeloid-antigen expression in adult acute lymphoblastic leukemia. N Engl J Med. 1987;317:1156-1157.
60. Bene MC, Bernier M, Casasnovas RO, Castoldi G, Knapp W, Lanza F, Ludwig WD, Matutes E, Orfao A, Sperling C, Vant't Veer MB for the European Group for the Immunologic Classification of Leukemias (EGIL). The reliability and specificity of c-kit for the diagnosis of acute leukemias and undifferentiated leukemias. Blood 1998; 92:596-599.
61. Menendez P, Cañizo MC, Orfao A. Immunophenotypic characteristics of PB-mobilised CD34+ hematopoietic progenitor cells. J Biol Regul Homeost Agents 2001;15:53-61.
62. Sperr WR, Jordan JH, Baghestanian M, Kiener HP, Samorapoompichit P, Semper H, Hauswirth A, Schernthaner GH, Chott A, Natter S, Kraft D, Valenta R, Schwartz LB, Geissler K, Lechner K, Valent P. Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood 2001;98:2200-2209.
63. Escribano L, Diaz-Agustin B, López A, Núñez R, Prados A, Orfao A on behalf of the Spanish Network on Mastocytosis (REMA). Immunophenotypic analysis of mast cells in mastocytosis: when and how to do it? Proposals of the Spanish Network on Mastocytosis (REMA). Clinical Cytometry 2004 (in press). DOI: 10.1002/cyto.b.10072.
64. San Miguel JF, Gonzalez M, Canizo MC, Anta JP, Zola H, Lopez Borrasca A. Surface marker analysis in acute myeloid leukaemia and correlation with FAB classification. Br J Haematol 1986;64:547-560.
65. Loken MR, Shah VO, Dattilio KL, Civin CI. Flow cytometric analysis of human bone marrow: I. Normal erythroid development. Blood 1987; 69:255-263.
66. San Miguel JF, González M, Cañizo MC, Ojeda E, Orfao A, Moro MJ, Fisac P, Romero M, Lopez Borrasca A. Leukaemias with megakaryoblastic involvement: clinical, hematological and immunological characteristics. Blood 1988;72:402-407.
67. hi dendritic cell malignancies. Haematologica 2004 (in press).
68. + malignancies. Blood 2002;99:1556-1563.
69. Bain BJ, Barnett D, Linch D, Matutes E, Reilly JT. General Haematology Task Force of the British Committee for Standards in Haematology (BCSH), British Society of Haematology: revised guidelines on immunophenotyping in acute leukaemias and chronic lymphoproliferative disorders. Clin Lab Haematol 2002;24:1-13.
70. Casasnovas RO, Slimane FK, Garand R, Faure GC, Campos L, Deneys V, Bernier M, Falkenrodt A, Lecalvez G, Maynadie M, Bene MC. Immunological classification of acute myeloblastic leukemias: relevance to patient outcome. Leukemia 2003;17:515-527.
71. San Miguel JF, Vidriales MB, Lopez-Berges MC, Diaz-Mediavilla J, Gutierrez N, Cañizo C, Ramos F, Calmuntia MJ, Perez JJ, Orfao A. Early immunophenotypical evaluation of minimall disease (MRD) in AML identifies different patient risk-groups and may contribute to post-induction treatment stratification. Blood 2001;98:1746-1751.
72. San Miguel JF, Martinez A, Macedo A, Vidriales MB, Lopez-Berges C, Gonzalez M, Caballero D, Garcia-Marcos MA, Ramos F, Fernandez-Calvo J, Calmuntia MJ, Diaz-Mediavilla J, Orfao A. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 1997; 90:2465-2470.
73. Kern W, Danhauser-Riedl S, Ratei R, Schnittger S, Schoch C, Kolb HJ, Ludwig WD, Hiddemann W, Haferlach T. Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow. Haematologica 2003;88:646-653.
74. Sievers EL, Lange BJ, Alonzo TA, Gerbing RB, Bernstein ID, Smith FO, Arceci RJ, Woods WG, Loken MR. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective children's cancer group study of 252 patients with acute myeloid leukemia. Blood 2003;101:3398-3406.
75. Venditti A, Buccisano F, Del Poeta G, Maurillo L, Tamburini A, Cox C, Battaglia A, Catalano G, Del Moro B, Cudillo L, Postorino M, Masi M, Amadori S. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 2000;96: 3948-3952.
76. Macedo A, Orfao A, Vidriales MB, Lopez-Berges MC, Valverde B, Gonzalez M, Caballero MD, Ramos F, Martinez M, Fernandez-Calvo J, San Miguel JF. Characterization of aberrant phenotypes in AML as a tool for detection of minimal residual disease. Ann Hematol 1995;70: 189-194.
77. Baer MR, Stewart CC, Lawrence D, Arthur DC, Mrozek K, Strout MP, Davey FR, Schiffer CA, Bloomfield CD. Acute myeloid leukemia with 11q23 translocations: myelomonocytic immunophenotype by multiparameter flow cytometry. Leukemia 1998;12:317-325.
78. Muñoz L, Nomdedeu JF, Villamor N, Guardia R, Colomer D, Ribera JM, Torres JP, Berlanga JJ, Fernández C, Llorente A, Queipo de Llano MP, Sánchez JM, Brunet S, Sierra J, Spanish CETLAM group. Acute myeloid leukemia with MLL rearrangements: clinico-biologic features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells. Leukemia 2003;17:76-82.
79. Hurwitz CA, Raimondi SC, Head D, Krance R, Mino J Jr, Kalwinsky DK, Ayers GD, Behm FG. Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children. Blood 1992;80:3182-3188.
80. Haas OA, Koller U, Grois N, Nowotny H. Immunophenotype of hematologic neoplasms with a translocation t(8;21). Recent Results Cancer Res 1993;131:361-368.
81. Muñoz L, Nomdedeu JF, Brunet S, Villamor N, Tormo M, Sierra J. CD56 expression could be associated with monocytic differentiation in acute myeloid leukemia with t(8;21). Haematologica 2001;86:763-764.
82. Muñoz L, Aventin A, Villamor N, Junca J, Acebedo G, Domingo A, Rozman M, Torres JP, Tormo M, Nomdedeu J. Immunophenotypic findings in acute myeloid leukemia with FLT3 internal tandem duplication. Haematologica 2003;88:637-645.
83. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100: 2292-2302.
84. Killick S, Matutes E, Powles RL, Hamblin M, Swansbury J, Treleaven JG, Zomas A, Atra A, Catovsky D. Outcome of biphenotypic acute leukemias. Haematologica 1999;84:699-706.
85. Vidriales MB, Perez JJ, Lopez-Berges MC, Gutierrez N, Ciudad J, Lucio P, Vazquez L, Garcia-Sanz R, del Cañizo MC, Fernández-Calvo ez-Calvo J, Ramos F, Rodriguez MJ, Calmuntia MJ, Porwit A, Orfao A, San Miguel JF. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. Blood 2003;101:4695-4700.
86. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama I, Aul C, Mufti G, Bennett J. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088.
87. San Miguel JF, Hernandez JM, Gonzalez-Sarmiento R, Gonzalez M, Sanchez I, Orfao A, Canizo MC, Lopez Borrasca A. Acute leukemia after a primary myelodysplastic syndrome: immunophenotypic, genotypic, and clinical characteristics. Blood 1991;78:768-774.
88. Bene MC. Immunophenotyping of myelodysplasia. Haematologica 2003;88:363.
89. Ramos F, Fernandez-Ferrero S, Suarez D, Barbon M, Rodriguez JA, Gil S, Megido M, Ciudad J, Lopez N, del Canizo C, Orfao A. Myelodysplastic syndrome: a search for minimal diagnostic criteria. Leuk Res 1999;23:283-290.
90. Maynadie M, Picard F, Husson B, Chatelain B, Cornet Y, Le Roux G, Campos L, Dromelet A, Lepelley P, Jouault H, Imbert M, Rosenwadj M, Verge V, Bissieres P, Raphael M, Bene MC, Feuillard J, Groupe D'Etude Immunologique des Leucemies, (GEIL). Immunophenotypic clustering of myelodysplastic sindromes. Blood 2002;100:2349-2356.
91. Stetler-Stevenson M, Arthur DC, Jabbour N, Xie XY, Molldrem J, Barrett AJ, Venzon D, Rick ME. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndromes. Blood 2001;98: 979-987.
92. Del Cañizo MC, Fernández E, López A, Vidriales B, Villaron E, Arroyo JL, Ortuno F, Orfao A, San Miguel JF. Immunophenotypic analysis of myelodysplastic syndromes. Haematologica 2003;88:400-405.
93. Wells DA, Benesch M, Loken MR, Vallejo C, Myerson D, Leisenring WM, Deeg HJ. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003;102:394-403.
94. Elguetany MT. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndromes. Blood 2002;99:391.
95. Stetler-Stevenson M, Rick M, Arthur D. Diagnosis flow cytometric immunophenotyping in myelodysplastic syndrome: the US-Canadian consensus recommendations on the immunophenotypic analysis of hematological neoplasia by flow cytometry apply. Blood 2002;99: 391-392.